Lifevantage Corp Stock Price, News & Analysis

LifeVantage (Nasdaq: LFVN) announced a breakthrough study revealing the synergistic effects of Protandim® Nrf2 Synergizer® and MindBody GLP-1 System™. When combined as the Healthy Weight Stack, these products activate 22 new genes that target age-related organ decline, supporting regeneration and repair of tissue cells, enhancing cellular communication, and improving overall organ health.

Key findings include:

• Enhanced Antioxidant Defense: Activation of four additional antioxidant pathways, improving cellular resilience against oxidative stress.
• Amplified Fat Metabolism: Activation of nine fat and fatty acid metabolism pathways, optimizing fat usage and breakdown, particularly in the midsection.
• Synergistic Organ Health Activation: Activation of 22 new genes aiding in cellular adhesion, pro-survival pathways, and chemical/electrical signaling, significantly improving organ strength and communication.

According to Lisa Barnes, VP of R&D and Regulatory, the Healthy Weight Stack strengthens cellular bonds and communication networks within organs, promoting graceful aging and optimal performance. Additional benefits include increased energy, mental sharpness, healthy digestion, and improved coordination. CEO Steve Fife emphasized the products' potential to enhance health and offer business opportunities within the LifeVantage community.

LifeVantage (Nasdaq: LFVN), a health and wellness company, announced its preliminary second-quarter revenue results for the fiscal year ending December 31, 2024. The company reported revenue of approximately $67.5 million, representing a 31% increase from the same period the previous year and a 43% sequential rise from the first fiscal quarter.

Active Account growth in the Americas saw a 22.7% increase year-over-year and a 25.4% rise sequentially. Globally, Active Accounts grew by 12.1% year-over-year and 18.5% sequentially.

LifeVantage also raised its fiscal 2025 revenue guidance to a range of $235 million to $245 million, up from the previously expected $200 million to $210 million. The company attributes this growth to the strong sales of the MindBody GLP-1 System™ launched in October in the United States, as well as exceptional execution in ramping up supply chain and fulfillment capacities to meet demand.

CEO Steve Fife highlighted the highest number of enrollments in a quarter since Q3 of fiscal 2019, indicating strong business momentum and a positive outlook for continued growth and shareholder value. Detailed profitability outlook will be provided in early February when the company reports its full fiscal Q2 results.

LifeVantage (LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the upcoming 27th Annual ICR Conference in Orlando, FL. The company will be represented by President and CEO Steve Fife and CFO Carl Aure, who are scheduled to present on Monday, January 13, 2025, at 10:30 a.m. Eastern Time.

Investors and interested parties can access the presentation through a webcast available on the News & Events section of LifeVantage's Investor Relations website. The conference is set to run from January 13-15, 2025.

LifeVantage (Nasdaq: LFVN), a leader in health and wellness, announced its participation in the Water Tower Fireside Chat Series on December 3, 2024. The event will feature presentations by Steve Fife, President and CEO, and Carl Aure, CFO, scheduled for 11:00 a.m. Eastern Time. The presentation will be webcasted and accessible via the company's Investor Relations website at https://lifevantage.gcs-web.com/.

LifeVantage (Nasdaq: LFVN) has reintroduced its TrueScience® TruePout Hydrating Lip Oil to the US market for Cyber Monday. The product is being sold as a three-pack with French Vanilla flavor and features plant-based ingredients. The lip oil offers hydration through plant-based squalane, exfoliation via pineapple extract, and nourishment from seed oils and fruit extracts. Available pricing tiers include Consultant Price at $75.99, Subscription Price at $85.49, and Retail Price at $94.99. The product is available exclusively through US Consultants and the LifeVantage website while supplies last.

LifeVantage (Nasdaq: LFVN), a health and wellness company focusing on cellular-level health products, has announced its participation in the upcoming Sidoti Micro Cap Conference. Steve Fife, President and CEO, and Carl Aure, CFO, will conduct virtual investor meetings and deliver a presentation on November 13, 2024, at 1:00 p.m. Eastern Time. The presentation will be available via live webcast through the company's Investor Relations website.

LifeVantage reported Q1 fiscal 2025 results with revenue of $47.2 million, down 8.1% year-over-year. Net income per diluted share increased to $0.14 from $0.05 in the prior year. The company launched the MindBody GLP-1 System™ on October 11th. Revenue declined 4.2% in Americas and 19.7% in Asia/Pacific & Europe. Despite lower revenues, adjusted EBITDA improved 11% to $4.4 million. The company maintains its fiscal 2025 guidance of $200-210 million in revenue and adjusted earnings per share of $0.70-$0.80.

LifeVantage (Nasdaq:LFVN) has announced that its Board of Directors has approved a quarterly cash dividend of $0.04 per share of common stock. The dividend will be paid on December 16, 2024 to stockholders of record at the close of business on December 2, 2024. LifeVantage is a health and wellness company focusing on products that activate optimal health processes at the cellular level.

LifeVantage (LFVN) announced results from a human clinical trial of their MindBody GLP-1 System™, showing a 140% average increase in GLP-1 levels and significant weight loss outcomes. The 12-week study involved 60 subjects with BMI≥25, divided into three groups. Key findings include: 92% of participants lost weight (average 11 pounds), 92% reduced total body fat, and 71% decreased visceral fat. Notably, participants reported improved relationships with food, with 95% experiencing decreased sugar cravings and 96% reducing portion sizes. The system uses natural ingredients to activate GLP-1 production without reported side effects.